Schrödinger (SDGR) Competitors

Roivant Sciences (NASDAQ:ROIV) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.

Does the MarketBeat Community believe in ROIV or SDGR?

Schrödinger received 1 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 58.33% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%
Schrödinger	Outperform Votes 56 58.33%	Underperform Votes 40 41.67%

Do institutionals & insiders hold more shares of ROIV or SDGR?

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 8.6% of Schrödinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings and valuation, ROIV or SDGR?

Roivant Sciences has higher earnings, but lower revenue than Schrödinger. Roivant Sciences is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$122.59M	64.03	$4.35B	-$0.15	-73.33
Schrödinger	$207.54M	9.20	$40.72M	-$2.57	-10.17

Do analysts recommend ROIV or SDGR?

Roivant Sciences presently has a consensus price target of $17.50, indicating a potential upside of 59.09%. Schrödinger has a consensus price target of $33.00, indicating a potential upside of 26.29%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Schrödinger	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media favor ROIV or SDGR?

In the previous week, Roivant Sciences had 9 more articles in the media than Schrödinger. MarketBeat recorded 19 mentions for Roivant Sciences and 10 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.92 beat Roivant Sciences' score of 0.69 indicating that Schrödinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrödinger	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, ROIV or SDGR?

Roivant Sciences has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Is ROIV or SDGR more profitable?

Schrödinger has a net margin of -91.84% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-119.54%	-14.05%	-12.81%
Schrödinger	-91.84%	-35.77%	-24.51%

Summary

Schrödinger beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.